MKI67 and neoplasm: In splenic MDSCs isolated from 4T1 tumor–bearing mice, PLX51107 significantly reduced Ki67 positivity at 72 h with a sublethal dose of 62.5 nM (50% vs. 34%, P < 0.05) (Supplemental Figure 7, C and D).